Xenetic Biosciences Inc (XBIO): 10-Q page 13 indicates: Our Phase 2 tr...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Xenetic Biosciences Inc (XBIO)

Reply Private New

Keep Last Read

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	9
Posts	836
Boards Moderated	0
Alias Born	06/24/2014

Re: RisingProfit post# 1307

Monday, 08/20/2018 4:36:06 PM

Monday, August 20, 2018 4:36:06 PM

10-Q page 13 indicates:
Our Phase 2 trial for XBIO-101 commenced patient dosing in October 2017. We have experienced slower progress in our Phase 2 trial than originally estimated, and therefore are unable to predict when preliminary data from this trial may be available.

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent XBIO News

Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 02:15:12 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 10:18:54 PM
Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 10:16:58 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:30:21 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:30:18 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:30:15 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:30:11 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 10:00:32 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/13/2023 10:00:18 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:30:10 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:00:42 PM
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 09/18/2023 04:21:48 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 12:05:09 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:30:48 PM

More XBIO News

InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow